Navigation Links
TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
Date:1/29/2009

SCOTTSDALE, Ariz. Jan. 29, 2008 TGen Clinical Research Services (TCRS) at Scottsdale Healthcare and Mayo Clinic are testing a new drug that may offer broad potential to treat solid tumors.

Clinical trials of the drug TH-302 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of the Phoenix-based Translational Genomics Research Institute (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona.

Dr. Glen Weiss, Director of Thoracic Oncology at TCRS at Scottsdale Healthcare, said the new drug appears promising and may be more effective and less toxic to healthy tissues than conventional drugs.

"TH-302 is a new, novel, small molecule that is activated under a metabolic condition characteristic of cancer cells hypoxia (lack of oxygen). The drug candidate may provide an opportunity to treat slowly dividing tumor cells within hypoxic regions that generally evade traditional chemotherapeutic agents and ultimately contribute to relapse," Dr. Weiss said.

Phase 1 and Phase 1/2 trials are underway to investigate the safety and activity of TH-302 in patients with advanced solid tumors. After evidence of tumor activity was observed in the Phase 1 trial in patients with advanced melanoma both non-small cell lung cancer and small cell lung cancer the study was expanded to further investigate TH-302 anti-tumor activity in these tumors. Both Phase 1 and 1/2 trials continue to enroll patients with other solid tumors. If successful, Phase 2 and 3 clinical trials will confirm the drug's effectiveness on solid tumors.

In cancer, as a tumor grows, it rapidly outgrows its blood supply, leaving portions of the tumor with regions where the oxygen concentration is significantly lower than in healthy tissues. This condition is called tumor hypoxia. Several studies have shown that higher levels of tumor hypoxia correlate with poor treatment outcomes for a varie
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
2. Genome Medicine: Bridging the gap between research and clinical practice
3. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
4. In just 5 years, gene discovery to clinical trial of potential treatment
5. New book helps medical students master clinical skills
6. Biochemistry of human physiology in health and disease is focus of updated clinical text
7. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
8. A new journal where molecular biology meets clinical research
9. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
10. Clinical trial for new tuberculosis vaccine
11. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... BELLINGHAM, Washington, USA -- "Nature has developed, very cleverly, ... we desire in optical design," said Joseph Shaw, director ... "As we explore surfaces and structures at the nanoscale, ... presented in San Diego in August during a conference ... by Shaw and Rongguang Liang of the University of ...
(Date:9/17/2014)... (Hospital del Mar Medical Research Institute) and at the ... study in eLife showing that RNA called ... of new proteins, some of which could have important ... from the instructions found in an RNA molecule. However, ... information for the synthesis of proteins, meaning it is ...
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Parts of genome without a known function may play a key role in the birth of new proteins 2Abnormal properties of cancer protein revealed in fly eyes 2
... Farmers who don,t rely on or want to minimize the ... battle against aggressive perennial weeds. In ongoing research at the ... be a worthy contender as a summer smother crop. ... The Sudangrass creates shade so photosynthesis cannot occur in the ...
... WEST LAFAYETTE, Ind. - Wheat plants found to ... in reinforcements to build up rigid defenses. Christie ... Agriculture,s Agricultural Research Service and a Purdue University associate ... by Hessian fly larvae increased production of surface waxes ...
... Bringing the power of synchrotron light to Minnesota,s ... of a Memorandum of Agreement (MOA) signed today between ... synchrotron facility, the Canadian Light Source (CLS). ... and product outcomes while improving operating efficiency for both ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3Resistant wheat rebuilds cell walls when attacked by Hessian flies 2BioBusiness Alliance, Canadian Light Source Synchrotron sign agreement 2
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... & Young LLP ("EY") that it was resigning effective September ... to the Company on September 15, 2014 and reported in ... PDL has issued the following statement in response to ... inquiries on the reason for the resignation of EY.  We ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2
... Owner of PHC Consulting) hasn't felt a down economy at all. ... in the medical industry (laboratory clinical and research, physician call points, ... for revenues and Peggy attributes that growth to a strong web ... ...
... PALO ALTO, Calif., June 25 Cell Biosciences, ... systems,to life science researchers, today announced three important ... named President and Chief Executive Officer. From 1998,through ... for Molecular,Devices Corporation where he helped build the ...
... U.S. Food and Drug,Administration (FDA) Advisory Committee ... the approval of tolvaptan, Otsuka Pharmaceutical,Development & ... hyponatremia., "Otsuka is pleased that the ... tolvaptan, an investigational selective,V2-vasopressin receptor antagonist," said ...
Cached Biology Technology:Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2Cell Biosciences Announces New Leadership 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2